10 PhD Projects Marie Curie European Industrial Doctorate (EID) 2809 views

PhD Projects Marie Curie European Industrial Doctorate (EID) training network funded by the European Commission

I-Direct is a Marie Curie European Industrial Doctorate (EID) training network funded by the European Commission within the Horizon 2020 research and innovation action.

Duration: The 10 students will start between Jan 2019 and Jan 2020. Each position will be appointed for 36 months and dedicated to the following projects/partner labs:

1. University Medical Center Groningen (UMCG) Netherlands
2. Universitätsklinikum Würzburg (UKW), Germany
3. InoCure SRO (INCU), Czech Republic
4. Surflay Nanotec GmbH (SURF), Germany
5. Kahr Medical LTD (KM), Israel

ELIGIBILITY Conditions:

1. An early stage researcher (ESR) is defined as a student being in the first four years of his/her research career at the time of the recruitment and a student who does not have a doctoral degree.
2. The research career starts after the degree that enables a student to proceed with a PhD (usually, the Master degree).

Application Procedure:

Send your complete application before June 30, 2019 as a single PDF file (5 MB max.) to i-direct@onco.umcg.nl.

1. A cover letter, stating your research motivation and interests; including relevant background.
2. In addition, provide a ranked list of at least 3 ESR projects you would like to work on.
3. CV (with list of publications or poster presentations)
4. Two letters of recommendation

Project Details

1. ESR 1: Development and preclinical validation of tumour-selective PD-1/PD-L1 immunotherapeutics and drug delivery systems
2. ESR 2: Cancer immunomodulation by tumour-selective targeting of innate immune checkpoints
3. ESR 3: Development of Adenosine-2A-Receptor (A2AR)-targeting bispecific antibodies and preclinical validation tools
4. ESR 4: Development of stimuli-sensotive particles for tumour-selective targeting of TIM-3/Galectin-9
5. ESR 5: Targeted inhibition of novel immune checkpoints
6. ESR 6: Development and characterization of antibody fusion proteins with tumourrestricted FcγR-independent co-stimulatory activity by targeting CD70
7. ESR 7: Development and characterization of antibody fusion proteins with tumourrestricted FcγR-independent co-stimulatory activity by targeting PD-L1
8. ESR 8: Development of stimuli-sensitive nanoparticles and in vivo evaluation of immunestimulatory TNFSF ligand fusion proteins with FAP-restricted activity
9. ESR 9: Development of immunomodulatory Dual Signalling Proteins (DSPs) for cancer immunotherapy
10. ESR 10: Nanoparticles for targeted delivery to tumours